Correction: Bispecific Nanobodies Targeting Bet v 1 and ICAM-1 Reduce Penetration of Bet v 1 in Respiratory Epithelial Cells
By
Ines Zettl
Isabella Ellinger
Mohammed Zghaebi
Sarah Jance
Vanessa Izewski
Anja Drescher
Heimo Breiteneder
Manuel Röck
Martin Tollinger
Julia Eckl-Dorna
Sergei V. Tillib
Sabine Flicker
September 11, 2026
Clinical Scorecard: Correction: Bispecific Nanobodies Targeting Bet v 1 and ICAM-1 Reduce Penetration of Bet v 1 in Respiratory Epithelial Cells
At a Glance
Category Detail
Condition Allergen Penetration in Respiratory Epithelial Cells Key Mechanisms Transcytosis and paracellular penetration due to epithelial barrier damage Target Population Individuals sensitized to birch pollen allergens Care Setting Immunology and Allergy Research
Key Highlights
Bispecific nanobodies target Bet v 1 and ICAM-1. Local administration of nanobodies offers rapid onset and reduced systemic exposure. Bet v 1 actively penetrates healthy respiratory epithelial cells. Transcription of alarmins like IL-33 is induced by Bet v 1 in airway epithelium. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with birch pollen allergy
Initial nanobodies for inhaled delivery evaluated in preclinical models.
Clinical Best Practices
Utilize bispecific nanobodies for targeted allergen blocking. Consider local administration to minimize systemic side effects. Related Resources & Content
